Jeremie Calais
Overview
Explore the profile of Jeremie Calais including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
3279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murthy V, Ludwig V, Gafita A, Hope T, Calais J
J Nucl Med
. 2025 Feb;
PMID: 40015925
Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). Lu PSMA-targeted radiopharmaceutical therapy (RPT) enables direct delivery of β-radiation...
2.
Ells Z, Ludwig V, Weiner A, Kimura K, Farolfi A, Chamie K, et al.
Methods
. 2025 Feb;
236:10-16.
PMID: 39988309
Introduction: Surgeons commonly use cross sectional images to plan and prepare for surgical procedures. However, cognitively translating 2D images to surgical settings can be difficult and lead to sub-optimal resections....
3.
Czernin J, Bodei L, Modlin I, Calais J
J Nucl Med
. 2025 Feb;
66(3):333-336.
PMID: 39915128
No abstract available.
4.
Lehrer E, Khunsriraksakul C, Garrett S, Trifiletti D, Sheehan J, Guckenberger M, et al.
Crit Rev Oncol Hematol
. 2025 Jan;
208:104631.
PMID: 39864534
There is much debate regarding optimal selection in patients with metastatic cancer who should undergo local treatment (surgery or radiation treatment) to the primary tumor and/or metastases. Additionally, the optimal...
5.
Unterrainer L, Hope T, Fendler W, Grogan T, Ndlovu H, Armstrong W, et al.
J Nucl Med
. 2025 Jan;
66(1):54-60.
PMID: 39753363
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria....
6.
Holzgreve A, Armstrong W, Clark K, Benz M, Smith C, Djaileb L, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2452971.
PMID: 39752157
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with...
7.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...
8.
Hope T, Calais J, Goenka A, Haberkorn U, Konijnenberg M, McConathy J, et al.
J Nucl Med
. 2024 Nov;
66(1):26-33.
PMID: 39572227
No abstract available.
9.
Wu Q, Shao H, Zhai W, Huang G, Liu J, Calais J, et al.
Nat Rev Urol
. 2024 Nov;
PMID: 39543358
The clinical diagnosis of renal cell carcinoma (RCC) is constantly evolving. Diagnostic imaging of RCC relying on enhanced computed tomography (CT) and magnetic resonance imaging (MRI) is commonly used for...
10.
Armstrong W, Kishan A, Booker K, Grogan T, Elashoff D, Lam E, et al.
Eur Urol
. 2024 Nov;
87(1):97-99.
PMID: 39521695
No abstract available.